Latest Revenue Growth News

Platformo Ltd’s Biztrak software arm returned to positive cash flow and profitability in Q4 2025, driven by strategic cost control and digital expansion despite regulatory headwinds in Malaysia.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Group One Capital Limited has reported a remarkable 246% increase in revenue for the half-year ending December 2025, alongside expanding its structured funding facilities beyond $240 million through its subsidiary FSU Capital.

Wellnex Life reports a significant turnaround with a 31.5% revenue increase and near break-even operating cash flow in the December quarter, driven by strategic brand consolidation and cost discipline.

Elixinol Wellness Ltd reported a 9.5% revenue increase in Q4 FY25 alongside a 30% cut in operating costs, achieving its first underlying operating cash flow positive quarter. The company’s strategic acquisitions and e-commerce growth underpin a clear path to profitability.

Zimi Limited has reported a striking 300% year-on-year revenue surge alongside the industrialisation of its next-generation Senoa Matter smart home range, signalling a pivotal moment in its growth and market positioning.

Aerometrex Limited has reported record first half revenue and EBITDA for the six months ending December 2025, driven by strong MetroMap subscription growth and a rebound in LiDAR sales.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

Knosys reports steady revenue growth and a strategic partnership to upgrade its GreenOrbit platform, while accelerating development of its AI-powered Libero X library solution for a global launch next year.

Mayne Pharma delivered a robust FY25 performance with a 105% surge in underlying EBITDA and launched key dermatology products as it outlines a strategic growth path for FY26.

Appen Limited delivered a robust Q4 FY25, driven by explosive growth in its China segment and strong gains in generative AI projects globally, boosting revenue and profitability significantly.

BetMakers Technology Group reported a robust Q2 FY26 with positive adjusted EBITDA and significant contract wins poised to fuel growth in the second half of the year.